Analytical Data
-
Gene name
ideZ
- Application
-
Species
Streptococcus equi subsp. zooepidemicus
-
Source
E. coli
-
Tag
C- 12xHis
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q0PIW1
-
Expression Region
35-349aa
-
Molecular Weight
37.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IdeZ, an endopeptidase derived from the bacterium *Lactococcus lactis*, exhibits unique properties that make it a significant candidate for biotechnological and therapeutic applications. It specifically cleaves immunoglobulin G (IgG) molecules at a designated site, yielding functional Fab fragments that can be utilized in various biomedical applications, including antibody engineering and the development of new immunotherapies. The enzyme's specificity for IgG provides advantages in producing antibody fragments with retained antigen-binding capabilities while avoiding the potential immunogenicity associated with whole antibodies. The interest in IdeZ has grown substantially in the field of protein engineering, particularly due to its ability to help produce monoclonal antibodies and improve the efficacy of antibody-based drugs. Researchers have focused on optimizing the production and activity of IdeZ, exploring its structural characteristics to enhance its stability and reactivity under physiological conditions. Additionally, the enzyme's potential role in therapeutic settings, such as targeted drug delivery and cancer treatment, continues to drive investigations into its biochemical properties and mechanisms of action. Consequently, IdeZ represents a promising subject for future studies aimed at unraveling its full potential in both basic research and clinical applications.
